Devonian Health Group (TSXV:GSD) Moat Score: 1/10 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:GSD Devonian Health Group Inc TSXV:GSD
39 GF Score
Price C$10.14
! 7 Warning Signs
View Full Analysis

What is Devonian Health Group Moat Score?

Devonian Health Group TSXV:GSD 39 Moat Score is 1 as of Aug. 02, 2026. GuruFocus rates TSXV:GSD with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 1,394 Biotechnology companies, Devonian Health Group ranks worse than 52.3% on this metric.

Devonian Health Group has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

Devonian Health Group has No Moat: Devonian Health Group has minimal market presence and lacks significant intellectual property or regulatory barriers. Its competitive advantages are very weak and transient, resulting in a low moat score.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Devonian Health Group might have No Moat - Very weak/transient advantages.

Devonian Health Group  (TSXV:GSD) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Devonian Health Group Moat Score Related Terms

TSXV:GSD vs VRTX, REGN, RVMD: Moat Score Comparison

For the Biotechnology subindustry, Devonian Health Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Devonian Health Group Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Devonian Health Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Devonian Health Group's Moat Score falls into.


TSXV:GSD
39GF Score
Devonian Health Group Inc TSXV:GSD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
Devonian Health Group (TSXV:GSD) has a Moat Score of 1 as of Aug. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Devonian Health Group ranks #729 out of 1394 companies in the Biotechnology industry, placing it in the top 52.3%.
Is Devonian Health Group's Moat Score too high?
Devonian Health Group's current Moat Score is 1. The Biotechnology industry median Moat Score is 2.00. Devonian Health Group's value of 1 is 50% below this industry median. Based on the distribution chart, Devonian Health Group ranks #729 out of 1394 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #729 out of 1394 companies for Moat Score. This places Devonian Health Group in the lower half of its industry. The industry median Moat Score is 2.00. Devonian Health Group's value of 1 is 50% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devonian Health Group's current Moat Score of 1 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Devonian Health Group (TSXV:GSD) has a current Moat Score of 1. The current Moat Score is 1 and 50% below the Biotechnology industry median of 2.00. Devonian Health Group's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Devonian Health Group (TSXV:GSD), the current Moat Score is 1 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Devonian Health Group Business Description

Other Exchanges DVHGF:USA
Address 360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
39GF Score

Get the complete analysis for TSXV:GSD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$10.14
Price